BioSpace News Archive

The partial clinical hold follows Foghorn’s voluntary pause of the study and is due to one patient developing irregular heartbeat following treatment with FHD-609.

For those looking to transition out of academia, moving into a government role could be one of the most rewarding pathways available.

The regulatory filing puts the company alongside Vertex and CRISPR, which also await FDA approval for their SCD gene therapy.

Tuesday, the FDA approved Qalsody—formerly tofersen—on a conditional basis to treat SOD1-ALS.

Vedanta will use the funds to advance its lead asset VE303 in clostridioides difficile infection and support the development of another candidate in ulcerative colitis.

Govorestat failed its primary composite measure but showed signals of efficacy, leading the company to push forward with an NDA.

Morphic Therapeutic today reported corporate highlights and financial results for the first quarter 2023.

ALX Oncology Holdings Inc. today announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA.

Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has entered into an agreement with Unio Health Partners (formerly Genesis Research), to conduct a Phase I clinical study titled, “Micro Ultra-Sound Guided, Transperineal Focal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Morphic Therapeutic today reported positive topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with moderate to severe ulcerative colitis (UC).